ECSP20057847A - Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano - Google Patents
Moduladores de sting (estimulador de genes de interferón) a base de ciclopentanoInfo
- Publication number
- ECSP20057847A ECSP20057847A ECSENADI202057847A ECDI202057847A ECSP20057847A EC SP20057847 A ECSP20057847 A EC SP20057847A EC SENADI202057847 A ECSENADI202057847 A EC SENADI202057847A EC DI202057847 A ECDI202057847 A EC DI202057847A EC SP20057847 A ECSP20057847 A EC SP20057847A
- Authority
- EC
- Ecuador
- Prior art keywords
- stimulator
- cyclopentane
- interferon genes
- compounds
- sting modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643467P | 2018-03-15 | 2018-03-15 | |
| US201862666204P | 2018-05-03 | 2018-05-03 | |
| US201862742532P | 2018-10-08 | 2018-10-08 | |
| US201962809990P | 2019-02-25 | 2019-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20057847A true ECSP20057847A (es) | 2021-04-29 |
Family
ID=66103038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202057847A ECSP20057847A (es) | 2018-03-15 | 2020-09-15 | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10538542B2 (enExample) |
| EP (1) | EP3765474B1 (enExample) |
| JP (1) | JP7266942B2 (enExample) |
| KR (1) | KR20200131878A (enExample) |
| CN (1) | CN111918871A (enExample) |
| AU (1) | AU2019234043A1 (enExample) |
| BR (1) | BR112020018593A2 (enExample) |
| CA (1) | CA3093631C (enExample) |
| CL (1) | CL2020002352A1 (enExample) |
| CR (1) | CR20200382A (enExample) |
| DO (1) | DOP2020000160A (enExample) |
| EC (1) | ECSP20057847A (enExample) |
| ES (1) | ES2923298T3 (enExample) |
| IL (1) | IL277278A (enExample) |
| MA (1) | MA52012A (enExample) |
| MX (1) | MX2020009587A (enExample) |
| NI (1) | NI202000058A (enExample) |
| PE (1) | PE20210412A1 (enExample) |
| PH (1) | PH12020551486A1 (enExample) |
| PY (1) | PY1919127A (enExample) |
| RU (1) | RU2020130048A (enExample) |
| SG (1) | SG11202008102VA (enExample) |
| TW (1) | TWI741268B (enExample) |
| UY (1) | UY38145A (enExample) |
| WO (1) | WO2019175776A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10538542B2 (en) * | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| KR20220070254A (ko) | 2019-09-25 | 2022-05-30 | 화이자 인코포레이티드 | Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제 |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| WO2022122613A1 (en) * | 2020-12-08 | 2022-06-16 | F. Hoffmann-La Roche Ag | Novel synthesis of phosphorodithioate oligonucleotides |
| US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CR20160564A (es) * | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10538542B2 (en) * | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
-
2019
- 2019-03-11 US US16/297,910 patent/US10538542B2/en active Active
- 2019-03-11 TW TW108108048A patent/TWI741268B/zh not_active IP Right Cessation
- 2019-03-12 BR BR112020018593-0A patent/BR112020018593A2/pt not_active IP Right Cessation
- 2019-03-12 CN CN201980019494.9A patent/CN111918871A/zh active Pending
- 2019-03-12 KR KR1020207029472A patent/KR20200131878A/ko not_active Withdrawn
- 2019-03-12 JP JP2020548916A patent/JP7266942B2/ja active Active
- 2019-03-12 ES ES19717149T patent/ES2923298T3/es active Active
- 2019-03-12 AU AU2019234043A patent/AU2019234043A1/en not_active Abandoned
- 2019-03-12 MX MX2020009587A patent/MX2020009587A/es unknown
- 2019-03-12 EP EP19717149.9A patent/EP3765474B1/en active Active
- 2019-03-12 CA CA3093631A patent/CA3093631C/en active Active
- 2019-03-12 MA MA052012A patent/MA52012A/fr unknown
- 2019-03-12 RU RU2020130048A patent/RU2020130048A/ru unknown
- 2019-03-12 CR CR20200382A patent/CR20200382A/es unknown
- 2019-03-12 SG SG11202008102VA patent/SG11202008102VA/en unknown
- 2019-03-12 WO PCT/IB2019/052009 patent/WO2019175776A1/en not_active Ceased
- 2019-03-12 PE PE2020001412A patent/PE20210412A1/es unknown
- 2019-03-13 UY UY38145A patent/UY38145A/es not_active Application Discontinuation
- 2019-03-13 PY PY201901919127A patent/PY1919127A/es unknown
- 2019-12-04 US US16/702,738 patent/US10968242B2/en active Active
-
2020
- 2020-08-25 DO DO2020000160A patent/DOP2020000160A/es unknown
- 2020-08-28 NI NI202000058A patent/NI202000058A/es unknown
- 2020-09-10 IL IL277278A patent/IL277278A/en unknown
- 2020-09-11 CL CL2020002352A patent/CL2020002352A1/es unknown
- 2020-09-12 PH PH12020551486A patent/PH12020551486A1/en unknown
- 2020-09-15 EC ECSENADI202057847A patent/ECSP20057847A/es unknown
-
2021
- 2021-03-03 US US17/190,924 patent/US20210230196A1/en not_active Abandoned
-
2023
- 2023-07-24 US US18/225,589 patent/US20230382932A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20057847A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| CL2020000299A1 (es) | Compuestos, composiciones y métodos. | |
| DOP2020000050A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| DOP2022000066A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| UY36285A (es) | Compuestos que inhiben la proteína mcl-1 | |
| CO2017012268A2 (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| ECSP20029790A (es) | Compuestos moduladores de sting y métodos de elaboración y uso | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino | |
| UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
| AR122310A1 (es) | Moduladores de sting (estimulador de genes de interferón) | |
| EA201892095A1 (ru) | Циклические динуклеотидные соединения и способы их применения |